ZNA Stuivenberg
Welcome,         Profile    Billing    Logout  
 22 Trials 
25 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Verheye, Stefan
NCT05033964: The DESyne BDS Plus RCT: A Randomized Clinical Trial to Assess the Elixir DESyne BDS Plus Drug Eluting Coronary Stent System for the Treatment of de Novo Native Coronary Artery Lesions

Active, not recruiting
2
200
Europe, RoW
Percutaneous Coronary Intervention with drug eluting stents
Elixir Medical Corporation
Coronary Artery Disease
12/22
03/26
CAPTURE, NCT03571789: Carotid Artery Implant for Trapping Upstream Emboli for Preventing Stroke in Atrial Fibrillation Patients

Active, not recruiting
N/A
25
Europe, RoW
Vine™
Javelin Medical
Atrial Fibrillation
12/18
11/28
BIOSOLVE-IV, NCT02817802: BIOTRONIKS - Safety and Performance in de NOvo Lesion of NatiVE Coronary Arteries With Magmaris- Registry:

Active, not recruiting
N/A
2066
Europe, RoW
Magmaris
Biotronik AG
Coronary Artery Disease
07/20
10/25
NCT04289870: Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study

Active, not recruiting
N/A
20
Europe, RoW
Trillium™
Innoventric LTD
Tricuspid Regurgitation
07/23
06/26
PINNACLE I, NCT05828173: A Clinical Trial to Assess the Elixir Medical LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter

Active, not recruiting
N/A
60
Europe
LithiX Coronary Hertzian Contact Intravascular Lithotripsy Catheter (LithiX Coronary HCIVLC; LithiX)
Elixir Medical Corporation
Coronary Artery Disease
04/24
09/24
CAPTURE2, NCT03892824: Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants

Active, not recruiting
N/A
100
Europe, RoW
Vine™ Embolic Protection System
Javelin Medical, Genae
Atrial Fibrillation, Stroke
11/22
10/24
NCT02710435: REDUCER-I: An Observational Study of the Neovasc Reducer™ System

Active, not recruiting
N/A
400
Europe
Reducer System, Reducer
Neovasc Inc., Shockwave Medical, Inc.
Angina Pectoris, Angina Pectoris, Stable, Chronic Stable Angina
11/23
12/28
NCT04091048: Optimize PRO Study

Active, not recruiting
N/A
800
Europe, Canada, US, RoW
Evolut™ PRO and Evolut™ PRO+ System (Evolut™ FX System for the addendum)
Medtronic Cardiovascular
Symptomatic Aortic Stenosis
12/23
12/24
CHANGE, NCT05853419: Change History and Adopt a Robotic SolutioN for anGioplasty procedurE

Recruiting
N/A
500
Europe, RoW
Robotic-assisted PCI
Robocath, European Cardiovascular Research Center
Coronary Disease
05/26
06/26
VENDITTI, Adriano
NCT03250338 / 2017-001600-29: Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R/R FLT3 Mutated AML

Recruiting
3
322
Europe, Canada, US
Crenolanib, Crenolanib besylate, Cytarabine, Mitoxantrone, Placebo Oral Tablet, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Relapsed/Refractory Acute Myeloid Leukemia With FLT3 Activating Mutations
10/24
10/24
IMPACT-AML, NCT06713837: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.

Not yet recruiting
3
339
Europe, RoW
High intensity therapies, Low intensity therapies
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European Leukemia Net, Fundacion Para La Investigacion Hospital La Fe, Ostdeutsche Studiengruppe Haematologie Und Onkologie e.V., Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, TIMELEX
Acute Myeloid Leukemia, Relapse/Recurrence
01/28
01/28
RIVER-81, NCT06191263: Safety and Efficacy of RVU120 Combined with Venetoclax for Treatment of Relapsed/Refractory AML

Recruiting
2
98
Europe
RVU120, SEL120, Venetoclax
Ryvu Therapeutics SA
Acute Myeloid Leukemia
02/26
09/26
RIVER-52, NCT06268574: Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML

Recruiting
2
94
Europe, Canada
RVU120, SEL120
Ryvu Therapeutics SA
Acute Myeloid Leukemia (AML), High-risk Myelodysplastic Syndrome
02/26
09/26
IMPACT STREAM, NCT06459024: Master Framework For Relapse or Refractory Acute Myeloid Leukemia

Recruiting
N/A
4000
Europe
Registration into the STREAM platform
Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori, Hospital Vall d'Hebron, Cyprus Institute of Neurology and Genetics, European LeukemiaNet, Fundacion Para La Investigacion Hospital La Fe, Ostedusche Hematology and Oncology Study Group, Ospedale Pediatrico Bambin Gesù, Czech Lymphoma Study Group, Charite University, Berlin, Germany, Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León, University of Bologna, Hannover Medical School, German Society for Pediatric Oncology and Hematology GPOH gGmbH, Toscana Life Sciences Sviluppo s.r.l., Lithuanian University of Health Sciences, Gruppo Italiano Malattie EMatologiche dell'Adulto, Time.Lex
Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
07/32
07/32
Bourgeois, Stefan
NCT05276297 / 2021-003567-10: A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy

Active, not recruiting
2
184
Europe, RoW
GSK3228836, Bepirovirsen, GSK3528869A, Control
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
02/26
02/26
NCT03866187 / 2017-001452-55: Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection

Terminated
1/2
135
Europe, RoW
ChAd155-hIi-HBV low dose formulation, ChAd155-hIi-HBV high dose formulation, HBc-HBs/AS01B-4 low dose formulation, HBc-HBs/AS01B-4 high dose formulation, MVA-HBV low dose formulation, MVA-HBV high dose formulation, Placebo
GlaxoSmithKline, GlaxoSmithKline Biologicals
Hepatitis B, Chronic
10/24
10/24
ANGUILLE, Sébastien
IMMUNICY-1, NCT04613557: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma

Active, not recruiting
1
18
Europe, US
CYAD-211, Endoxan, cyclophosphamide, Fludara, Fludarabine
Celyad Oncology SA
Relapse/Refractory Multiple Myeloma
12/22
02/37
Breems, Dimitri A
HOVON 156 AML, NCT04027309 / 2018-000624-33: A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy

Active, not recruiting
3
777
Europe, RoW
Gilteritinib, ASP2215, Midostaurin, Rydapt
Stichting Hemato-Oncologie voor Volwassenen Nederland, Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG), Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndrome With Excess Blasts-2
10/25
06/33
Predictor2, NCT03887156: Evaluation of a Donor Testing Kit for the Prediction of AGVHD in Patient Receiving a Peripheral Blood Stem Cell Allograft

Recruiting
2/3
227
Europe
Ex vivo capacities of CD4neg INkT expansion of the peripheral blood donor with the Predictor test
Assistance Publique - Hôpitaux de Paris, SATT, SNC Graft Versus Host Disease, Imagine Institute, Axonal-Biostatem, CERBA laboratory
Acute Myeloid Leukemia in Remission, Lymphoma in Remission, Non-progressive Myeloproliferative Syndrome, Myelodysplasia With Stable Blasts is Cell Number and < 10% of Blastocysts, Acute Leukemia Biphenotypic in Remission, Acute Lymphoblastic Leukemia
03/23
03/23
BYON4413.001, NCT06359002: Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.

Recruiting
1
100
Europe
BYON4413
Byondis B.V.
Relapsed / Refractory AML, Relapsed / Refractory MDS
12/26
03/27
Wu, Kalung
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
Batjoens, Hedwig
CAPTURE2, NCT03892824: Carotid Artery Implant for Preventing Stroke in Atrial Fibrillation Patients Taking Oral Anticoagulants

Active, not recruiting
N/A
100
Europe, RoW
Vine™ Embolic Protection System
Javelin Medical, Genae
Atrial Fibrillation, Stroke
11/22
10/24
NCT05477602: The Automated Calculation of AF Cycle Length and Complexity Using a Novel EP Recording System

Recruiting
N/A
30
Europe
Cardiac Ablation for the treatment of persistent Atrial Fibrillation, Persistent AF Ablation
CathVision ApS, AKRN Consulting
Atrial Fibrillation
12/24
12/25
GPfIRE, NCT06647485: Evaluation of the Impact of Pulsed Field Ablation on Autonomic Nervous System Modulation in Paroxysmal Atrial Fibrillation

Not yet recruiting
N/A
105
Europe
PF-only PVI, Hybrid PVI, RF-only PVI
VZW Cardiovascular Research Center Aalst, Biosense Webster, Inc.
Atrial Fibrillation (AF), Paroxysmal AF
07/25
07/26
Joris, Inge
NCT04289870: Innoventric Trillium™ Stent Graft First-in-Human (FIH) Study

Active, not recruiting
N/A
20
Europe, RoW
Trillium™
Innoventric LTD
Tricuspid Regurgitation
07/23
06/26
Lung, Wu Ka
No trials found

Download Options